During the first four years of this funding period, The Ohio State University Comprehensive Cancer Center (OSUCCC) has experienced growth and expansion of its Programs, primarily related to the opening of the Arthur G. James Cancer Hospital and Research Institute (CHRI) in July, 1990. The OSUCCC organization reflects importance. The OSUCCC Director also serves as the CHRI Director and oversees the CHRI administration. Of the 68 OSU interdisciplinary academic Centers, it is the only one whose director has a direct reporting relationship to the President and Board of Trustees of the University. The OSUCCC organizational model links all of the OSUCCC research Programs to the respective cancer disease sites. This reflects the OSUCCC leadership's recognition that one of its primary responsibilities involves facilitating, expanding, and expediting translational research activities. This application will describe the past accomplishments and future plans of the thirteen OSUCCC Programs which are served by thirteen OSUCCC shared services. It will also describe future plans for the next funding period which include the development of a major new Program in human cancer genetics. The request for support described in this application is a strong attempt by OSUCCC leadership to recognize its responsibility to the national community of NCI approved cancer Centers during this difficult time of budgetary constraints for support of NCI Centers. Accordingly, the budget request in this competitive renewal application for Year 21 represents a reduction in the prior year CCSG support. The total five-year requested support represents only a 17 percent increase from the prior funding period which is less than what would be expected from inflationary increases alone. This has been accomplished through utilizing non-CCSG sources of support for the OSUCCC. But it has been achieved primarily as an expression of the OSUCCC's effort to try to weigh its individual Center needs with the needs of all the other NCI approved cancer Centers and the contracted ability of the NCI budget to provide this support. The OSUCCC is proud of its past accomplishments and enthusiastically welcomes the challenges and opportunities described in this application for further expansion during the next five-year funding period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-23
Application #
2442915
Study Section
Cancer Center Support Review Committee (CCS)
Project Start
1977-07-01
Project End
1999-06-30
Budget Start
1997-09-12
Budget End
1998-06-30
Support Year
23
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Zhang, Bin; Nguyen, Le Xuan Truong; Li, Ling et al. (2018) Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med 24:450-462
Tasselli, Giorgia; Filippucci, Sara; Borsella, Elisabetta et al. (2018) Yeast lipids from cardoon stalks, stranded driftwood and olive tree pruning residues as possible extra sources of oils for producing biofuels and biochemicals. Biotechnol Biofuels 11:147
Moliva, J I; Hossfeld, A P; Canan, C H et al. (2018) Exposure to human alveolar lining fluid enhances Mycobacterium bovis BCG vaccine efficacy against Mycobacterium tuberculosis infection in a CD8+ T-cell-dependent manner. Mucosal Immunol 11:968-978
Suarez-Kelly, Lorena P; Akagi, Keiko; Reeser, Julie W et al. (2018) Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity. Cold Spring Harb Mol Case Stud 4:
Malpeli, Giorgio; Barbi, Stefano; Greco, Corinna et al. (2018) MicroRNA signatures and Foxp3+ cell count correlate with relapse occurrence in follicular lymphoma. Oncotarget 9:19961-19979
Talbert, Erin E; Lewis, Heather L; Farren, Matthew R et al. (2018) Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. J Cachexia Sarcopenia Muscle 9:358-368
Wang, Jin-Ting; Xie, Wen-Quan; Liu, Fa-Quan et al. (2018) NADH protect against radiation enteritis by enhancing autophagy and inhibiting inflammation through PI3K/AKT pathway. Am J Transl Res 10:1713-1721
Karpurapu, Manjula; Lee, Yong Gyu; Qian, Ziqing et al. (2018) Inhibition of nuclear factor of activated T cells (NFAT) c3 activation attenuates acute lung injury and pulmonary edema in murine models of sepsis. Oncotarget 9:10606-10620
Norquist, Barbara M; Brady, Mark F; Harrell, Maria I et al. (2018) Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 24:777-783
Addison, Daniel; Lawler, Patrick R; Emami, Hamed et al. (2018) Incidental Statin Use and the Risk of Stroke or Transient Ischemic Attack after Radiotherapy for Head and Neck Cancer. J Stroke 20:71-79

Showing the most recent 10 out of 2602 publications